The Glaucoma Screening Study was a longitudinal study at the
Wilmer Eye Institute, sponsored by the National Eye Institute, to
identify early risk factors for the development of glaucomatous field
loss in patients with ocular hypertension.
24 25 Primary
open-angle glaucoma was diagnosed during a comprehensive examination by
one of four study ophthalmologists. All patients with glaucoma had
intraocular pressure higher than 21 mm Hg on at least two occasions
before treatment. Visual field testing was performed annually using
Program 30-2 of the Humphrey Field Analyzer. This is a full-threshold
test of the central 30° field using a stimulus of size III and was
administered by trained technicians according to the study protocol for
testing.
26 Patients included in this study were those in
whom glaucoma had been diagnosed and who had at least 5 years of
follow-up (at least six visual field tests), whose visual acuity was
20/100 or better, and whose first two field test results in the study
were outside normal limits on the Glaucoma Hemifield
Test.
10 18 19 Only 0.6% of fields had false-positive
response rates of 50% or more, 2.2% had false-negative responses of
50% or more, and 3.8% had fixation losses of 50% or more. Fields
were not excluded on the basis of reliability criteria, because only a
small fraction of fields were grossly unreliable and because there was
no a priori reason to think that the comparison of the two methods
would be differentially affected by reliability.
The clinical assessment of visual field progression was performed by
two fellowship-trained glaucoma specialists who reviewed the sequence
of visual fields for each patient. The clinicians were provided with
individual printouts from the Humphrey programs but were not given the
GCP printouts or any other clinical information. Each sequence of
fields was classified as “definite progression,” “possible
progression,” “stable-improved,” or “too unreliable to
assess.” Each clinician independently assigned the sequences to one
of the categories. Differences between the two clinicians were
adjudicated, and one clinical assessment of progression was produced
from this adjudication. To compare the clinical assessment with the
statistical methods, eyes were classified as having incident
progression if both clinicians agreed that there had been “definite
progression.”
The classification system designed for the Early Manifest Glaucoma
Treatment study was used to identify incident progression of visual
field defects. Progression was defined as a statistically significant
deterioration (P < 0.05) on the pattern deviation
probability maps of the GCP printouts in at least three locations (not
necessarily contiguous) with confirmation on two consecutive tests in
the same locations. Improvement was defined as three locations that
improved (P < 0.05), and these improvements were
confirmed on two further tests. The test results were transferred to
Statpac for Windows (Humphrey) for analysis using the
commercially available GCP program. Humphrey Instruments also kindly
provided us with a version of Statpac for Windows software to analyze
data from pattern deviation maps. This definition of progression was
also applied to the GCP output based on commercially available total
deviation probability maps.
In the printout of the GCP for pattern deviation, the follow-up
probability maps sometimes have Xs at specific locations. The key on
the printout identifies these locations as “not in database,”
indicating that the baseline threshold values are too low or too high
for making effective comparisons. These locations were not used to
assess whether at least three locations had changed significantly from
the baseline values. If all locations in the sequence of the field for
an eye had these markings, the eye was classified as having no
progression, but an analysis of incidence was also performed in which
these eyes were removed from the numerator and denominator.
Written informed consent for participation in the Glaucoma Screening
Study was obtained from each patient. The study was given ethical
approval by the Joint Committee on Clinical Investigations of the Johns
Hopkins School of Medicine in compliance with the Declaration of
Helsinki regarding the protection of human subjects.